Gambogic acid increases the sensitivity to paclitaxel in drug-resistant triple-negative breast cancer via the SHH signaling pathway

Paclitaxel is the most frequently used therapy regimen for triple-negative breast cancer (TNBC). However, chemoresistance frequently occurs, leading to enhanced failure rates of chemotherapy in TNBC; therefore, novel biological therapies are urgently needed. Gambogic acid (GA) has potent anticancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yonghui, Sui, Yana, Tao, Yinggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797991/
https://www.ncbi.nlm.nih.gov/pubmed/31545492
http://dx.doi.org/10.3892/mmr.2019.10697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797991/
https://www.ncbi.nlm.nih.gov/pubmed/31545492
http://dx.doi.org/10.3892/mmr.2019.10697

Ejemplares similares